Core Viewpoint - The company has successfully completed its share repurchase program, acquiring a total of 194,100 shares, which represents 0.0344% of its total share capital of 564 million shares [1] Group 1: Share Repurchase Details - The share repurchase was conducted on January 20, 2026, through the Shanghai Stock Exchange via a centralized bidding trading method [1] - The highest transaction price for the repurchased shares was 103.78 RMB per share, while the lowest was 102.17 RMB per share [1] - The total amount spent on the share repurchase was 20.004 million RMB, excluding transaction fees [1] Group 2: Completion of Repurchase Program - The company has reached the lower limit of the repurchase fund total and has not exceeded the upper limit, indicating that the repurchase plan has been fully implemented [1]

Core Viewpoint - The company Baili Tianheng (688506) has received a formal acceptance notice from the National Medical Products Administration (NMPA) for its drug application of the EGFR×HER3 dual antibody ADC (iza-bren), indicating progress towards market approval [1] Group 1: Drug Development and Approval - The drug application (NDA) for iza-bren has been officially accepted based on the interim analysis results from a Phase III clinical trial for esophageal squamous cell carcinoma [1] - The independent data monitoring committee (iDMC) determined that the trial met its primary endpoints of progression-free survival (PFS) and overall survival (OS) during the pre-specified interim analysis [1] - Iza-bren has been included in the priority review list by the NMPA for the treatment of recurrent or metastatic esophageal squamous cell carcinoma [1]

资料显示，殷刘松，自2020年11月起加入集团，担任盛禾（中国）生物制药的首席执行官兼首席科学 官。其于2023年7月21日获委任为董事并于2023年7月22日获调任为执行董事且进一步获委任为公司首席 执行官兼首席科学官，负责集团日常运营及科学事务。 自2014年至2015年，殷刘松在制药公司辉瑞公司任博士后研究员，参与大分子药物的免疫原性研究。自 2015年3月至2020年10月他任职于金斯瑞生物科技股份有限公司并最后担任执行总监，主要负责生物制 药项目和探索平台。 殷刘松于2008年7月取得位于安徽省的中国科学技术大学生物科学学士学位，并于2014年4月进一步取得 位于马萨诸塞州的马萨诸塞大学陈曾熙医学院（原称马萨诸塞大学医学院）生物医学博士学位。 瑞财经 刘治颖 1月19日，盛禾生物-B(02898)公告，殷刘松已提出辞任公司执行董事、首席执行官兼首 席科学官，以追求彼其他个人及职涯发展，自2026年2月28日起生效。 | | | | 薪金及 | 提休福利 | | | | --- | --- | --- | --- | --- | --- | --- | | | 委任日期 | 董事抱金 | 其他福利 | ...

Core Insights - The National Medical Products Administration (NMPA) has accepted a new drug application for the first-in-class dual antibody ADC drug, iza-bren, developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after failure of PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1][2] - The application is based on positive results from a Phase III clinical trial, which met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis [1] - Esophageal cancer has a significant global burden, with approximately 510,000 new cases and 445,000 deaths annually, and China accounts for about 224,000 new cases, representing 43.8% of the global total [1] Group 1 - Iza-bren has shown anti-tumor activity, safety, and efficacy in a Phase Ib clinical study published in the journal Nature Medicine [2] - Currently, over 40 clinical studies are ongoing for iza-bren in China and the U.S., including 10 registration Phase III studies in China and 3 global pivotal registration studies [2] - Seven indications for iza-bren have been included in the breakthrough therapy designation list by the CDE, and one indication has been designated as breakthrough therapy by the FDA [2] Group 2 - There are currently only 10 new biological drugs approved for esophageal cancer treatment globally, with no ADCs approved yet [3] - If approved, BL-B01D1 will become the first ADC drug for the treatment of esophageal cancer worldwide [3]

Group 1 - The company, Watson Bio (300142), is closely monitoring the application of new technologies in vaccine product research and manufacturing [1] - The company advises investors to refer to its disclosed announcements for information regarding its research and technological reserves [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials for HLX701 in combination with Cetuximab and chemotherapy for advanced colorectal cancer [1] Group 1 - The clinical trials for HLX701 will be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - HLX701 is a recombinant human SIRPα-IgG4 Fc fusion protein injection, licensed from FBD Biologics Limited, with exclusive rights for development, production, and commercialization in specified regions [1] - As of the announcement date, there are no approved targeted CD47 SIRPα-Fc fusion proteins available globally [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its self-developed B023 cell injection, a Class I innovative biological product aimed at treating inoperable locally advanced or metastatic solid tumors that have failed standard treatments [1] Group 1: Product Development - The B023 cell injection is developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - iNKT cells can be used in allogeneic applications without causing graft-versus-host disease (GvHD) due to the lack of polymorphism in the CD1d molecule in the human population [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its self-developed B023 cell injection, marking a significant advancement in innovative biopharmaceuticals targeting late-stage or metastatic solid tumors that are not amenable to surgery [1] Group 1: Product Development - B023 cell injection is classified as a Class I innovative biopharmaceutical, specifically designed for patients with locally advanced or metastatic solid tumors that have failed standard treatments and lack effective therapeutic options [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) that can be applied universally without causing graft-versus-host disease (GvHD) [1] - The project has been entirely developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., and the company holds complete intellectual property rights for the product [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1] - There are currently no other products with the same indication and type available in the global market, highlighting the uniqueness of B023 [1]

Group 1 - The Shanghai CDC announced that community health service centers in Shanghai will provide free HPV vaccinations for girls who are 13 years old and born after November 10, 2011, allowing them to receive two doses of the bivalent HPV vaccine [1] - Cervical cancer is one of the most common malignant tumors in the female reproductive system, with an increasing incidence and younger onset in China. In 2022, there were 151,000 new cases and 56,000 deaths from cervical cancer in the country, equating to one woman diagnosed every four minutes and one death every ten minutes [1] Group 2 - Starting from November 10, 2025, the national immunization program will officially include the HPV vaccine for girls aged 13 and born after November 10, 2011, based on considerations of protection effectiveness, cost-effectiveness, and operational feasibility [4] - Evidence shows that completing the full course of HPV vaccination before the first sexual intercourse provides the best prevention against HPV infection and related diseases, with antibody levels in girls aged 9-14 being more than twice that of those aged 15 and above, and protection lasting at least 10 years [4] - The procurement results for the national immunization program revealed that two domestic bivalent HPV vaccines from Wantai Biological Pharmacy and Watson Biotech were awarded contracts at a unit price of 27.5 yuan per dose, with a total budget of approximately 254 million yuan [4] Group 3 - The Shanghai CDC recommends using the same manufacturer's bivalent HPV vaccine for both doses. If a girl has already received one dose of a non-immunization program HPV vaccine, she should communicate with the vaccination clinic to decide on the second dose [5] - The Shanghai CDC provides various platforms for appointment and information regarding vaccinations, including the "Suishenban" app and the Shanghai CDC WeChat public account [6] - In addition to the HPV vaccines included in the immunization program, Shanghai's vaccination clinics continue to offer non-immunization program HPV vaccines for women aged 9-45 and men aged 9-26 on a self-paid basis [6]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials for HLX701 in combination with Cetuximab and chemotherapy for advanced colorectal cancer [1] Group 1: Clinical Trial Approval - The approval allows for the clinical trials of HLX701 to be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - HLX701 is a recombinant human SIRPα-IgG4 Fc fusion protein injection [1] Group 2: Licensing and Development - HLX701 was licensed from FBD Biologics Limited in June 2025, granting exclusive rights for development, production, and commercialization in specified regions including mainland China, Hong Kong, Macau, Southeast Asia, the Middle East, and North Africa [1] - As of December 2025, the cumulative R&D investment for HLX701 by the group is approximately RMB 76.09 million, which includes licensing fees [1] Group 3: Market Context - As of the announcement date, there are no approved targeted CD47 SIRPα-Fc fusion proteins available globally [1]